NCT04891302 - The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19 | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

March 19, 2021

Primary Completion Date

July 5, 2021

Study Completion Date

July 8, 2021

Conditions

COVID-19

Interventions

DRUG

Clevudine

Clevudine 150mg (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days

DRUG

Placebo

Matching Placebo (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days

Trial Locations (11)

Chungnam National University Hospital, Daejeon

Ajou University Hospital, Gyeonggi-do

Korea University Ansan Hospital, Gyeonggi-do

Myongji Hospital, Gyeonggi-do

Gachon University Gil Medical Center, Incheon

Incheon Medical Center, Incheon

Inha University Hospital, Incheon

Kangnam Sacred Heart Hospital, Seoul

Korea University Anam Hospital, Seoul

Korea University Guro Hospital, Seoul

Seoul Medical Center, Seoul